Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J)
暂无分享,去创建一个
Hirokazu Takahashi | Naofumi Ono | Y. Eguchi | M. Ono | K. Anzai | T. Otsuka | H. Hyogo | Kenichi Tanaka | Takahisa Eguchi | Yoichiro Kitajima | I. Ozaki | Norimasa Araki | M. Yamaguchi | Y. Matsuda | Motoyasu Kojima | Y. Ide
[1] H. Brody. Fatty liver disease , 2017, Nature.
[2] T. Bailey. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. , 2013, The American journal of medicine.
[3] S. Ross,et al. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes , 2013, Current medical research and opinion.
[4] Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer? , 2013, JAMA internal medicine.
[5] Jodi B Segal,et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. , 2013, JAMA internal medicine.
[6] S. Gough,et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program , 2013, Alimentary pharmacology & therapeutics.
[7] M. Pirmohamed,et al. Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists , 2012, PloS one.
[8] M. Omata,et al. The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone , 2012, TheScientificWorldJournal.
[9] B. Bode. An overview of the pharmacokinetics, efficacy and safety of liraglutide. , 2012, Diabetes research and clinical practice.
[10] Y. Yılmaz,et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. , 2012, Acta gastro-enterologica Belgica.
[11] T. Kawaguchi,et al. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report , 2012, Case Reports in Gastroenterology.
[12] D. Sorescu,et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[13] J. Prins,et al. Update on incretin hormones , 2011, Annals of the New York Academy of Sciences.
[14] M. Vivarelli,et al. Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[15] R. Elashoff,et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.
[16] Z. Halpern,et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. , 2011, Journal of hepatology.
[17] Y. Terauchi,et al. Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice , 2011, Diabetes.
[18] C. Clar,et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis , 2010, BMC endocrine disorders.
[19] R. Pollom,et al. Liraglutide in clinical practice: dosing, safety and efficacy , 2010, International journal of clinical practice. Supplement.
[20] F. Anania,et al. Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.
[21] R. Cuddihy,et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.
[22] P. Brubaker. Minireview: update on incretin biology: focus on glucagon-like peptide-1. , 2010, Endocrinology.
[23] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[24] G. Musso,et al. Non‐alcoholic fatty liver disease from pathogenesis to management: an update , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[25] Hirokazu Takahashi,et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff , 2009, Journal of Gastroenterology.
[26] A. Vaag,et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.
[27] S. Caldwell,et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.
[28] J. Rosenstock,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.
[29] B. Zinman,et al. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.
[30] S. Colagiuri,et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[31] B. Bode,et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.
[32] D. Matthews,et al. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.
[33] L. Macconell,et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Clinical therapeutics.
[34] K. Ishikawa-Takata,et al. Exercise and physical activity reference for health promotion 2006 (EPAR2006) , 2007, Journal of epidemiology.
[35] J. Brodsky,et al. Molecular Pathogenesis of Alpha-1-antitrypsin Deficiency-associated Liver Disease: a Meeting Review in Recent Years, We Have Witnessed Several Important Paradigm Shifts in Understanding the Molecular Basis of Liver Disease in Alpha-1-antitrypsin (at) Deficiency. These Shifts Have Become Possible as , 2022 .
[36] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[37] D. Drucker. The biology of incretin hormones. , 2006, Cell Metabolism.
[38] F. Anania,et al. Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.
[39] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[40] P. Kar,et al. Non-alcoholic steatohepatitis. , 2005, The Journal of the Association of Physicians of India.
[41] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[42] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[43] T. Shibasaki,et al. Critical Role of cAMP-GEFII·Rim2 Complex in Incretin-potentiated Insulin Secretion* , 2001, The Journal of Biological Chemistry.
[44] Yasuhiro Sunaga,et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis , 2000, Nature Cell Biology.
[45] D A Follmann,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .
[46] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[47] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[48] S. Yamashita,et al. Abdominal fat: standardized technique for measurement at CT. , 1999, Radiology.
[49] S.,et al. Abdominal fat. , 1999, Harvard women's health watch.
[50] S. Haffner,et al. A Prospective Analysis of the HOMA Model: The Mexico City Diabetes Study , 1996, Diabetes Care.
[51] J K McLaughlin,et al. Pancreatitis and the risk of pancreatic cancer. , 1993, The New England journal of medicine.
[52] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[53] A. Andrén-sandberg,et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. , 1993, The New England journal of medicine.
[54] T. Sakata,et al. Charting of daily weight pattern reinforces maintenance of weight reduction in moderately obese patients. , 1992, The American journal of the medical sciences.
[55] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.